The global xerostomia (dry mouth disease) therapeutics market size reached US$ 714 Million in 2022. Looking forward, IMARC Group expects the market to reach US$ 893 Million by 2028, exhibiting a growth rate (CAGR) of 3.6% during 2023-2028.
Xerostomia, or dry mouth, refers to symptoms or sensations of oral dryness that are usually caused due to a decrease in the amount of saliva. This condition is triggered by the adverse effects of radioactivity in the neck and head, increasing consumption of antianxiety drugs, dehydration, diabetes, and Alzheimer’s disorder. It can be treated with the support of salivary pens or stimulants, artificial saliva, prescribed medications, and home remedies, including sipping water and moisturizing lips. Apart from this, the early diagnosis of salivary glands by practitioners and the usage of recommended mouth moisturizing products, such as over-the-counter (OTC) rinsing, can assist in lubricating the mouth. These treatments alleviate discomfort, prevent severe complications, fix taste disorders, and mitigate bad breath and taste disorders. Consequently, xerostomia therapeutics are used across several hospitals and clinics to deal with decreased salivary gland function.
The increasing incidences of dry mouth, especially amongst the geriatric population, due to medicine side-effects of radiotherapy and chemotherapy and the rising need for dry mouth relief products are primarily driving the market growth. Additionally, the growing uptake of several prescription-based toothpaste, vitamin gummies, and medicines for treating Sjogren’s syndrome, Alzheimer’s diseases, and human immunodeficiency virus (HIV) that cause xerostomia is acting as another growth-inducing factor. In line with this, the rising consumer awareness regarding the early diagnosis of xerostomia, significant enhancements in healthcare expenditure, and the advent of diverse diagnostic technologies are propelling the market growth. Moreover, the favorable initiatives being commenced by governments to sensitize consumers regarding the xerostomia disease, its symptoms, causes, and treatments are impelling the market growth. Apart from this, the easy availability of various therapeutic drugs and ongoing research and development (R&D) activities are creating a positive outlook for the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global xerostomia (dry mouth disease) therapeuticsmarket report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, drug type and distribution channel.
Breakup by Type:
Artificial Saliva/Saliva Substitutes
Breakup by Drug Type:
Breakup by Distribution Channel:
Breakup by Region:
Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Biotene (GSK plc), Parnell Pharmaceuticals Inc., Quest Products LLC, Saliwell Ltd, Sun Pharmaceutical Industries Limited and West-Ward Pharmaceutical (Hikma Pharmaceuticals plc).
Base Year of the Analysis
Type, Drug Type, Distribution Channel, Region
Asia Pacific, Europe, North America, Latin America, Middle East and Africa
United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support
PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report
The global xerostomia (dry mouth disease) therapeutics market was valued at US$ 714 Million in 2022.
We expect the global xerostomia (dry mouth disease) therapeutics market to exhibit a CAGR of 3.6% during 2023-2028.
The rising incidences of dry mouth disease, along with the growing consumer awareness regarding the early diagnosis of xerostomia, are primarily driving the global xerostomia (dry mouth disease) therapeutics market.
The sudden outbreak of the COVID-19 pandemic had led to the postponement of elective oral treatment procedures to reduce the risk of the coronavirus infection upon hospital visits and interaction with healthcare professionals, thereby negatively impacting the global market for xerostomia (dry mouth disease) therapeutics.
Based on the type, the global xerostomia (dry mouth disease) therapeutics market can be categorized into artificial saliva/saliva substitutes and salivary stimulants. Currently, artificial saliva/saliva substitutes account for the majority of the global market share.
Based on the drug type, the global xerostomia (dry mouth disease) therapeutics market has been segregated into OTC and prescription, where OTC currently holds the largest market share.
Based on the distribution channel, the global xerostomia (dry mouth disease) therapeutics market can be bifurcated into hospital pharmacy, retail pharmacy, and online pharmacy. Among these, retail pharmacy exhibits a clear dominance in the market.
On a regional level, the market has been classified into North America, Asia-Pacific, Europe, Latin America, and Middle East and Africa, where North America currently dominates the global market.
Some of the major players in the global xerostomia (dry mouth disease) therapeutics market include 3M Company, Biotene (GSK plc), Parnell Pharmaceuticals Inc., Quest Products LLC, Saliwell Ltd, Sun Pharmaceutical Industries Limited, and West-Ward Pharmaceutical (Hikma Pharmaceuticals plc).
Need more help?
Speak to our experienced analysts for insights on the current market scenarios.
Include additional segments and countries to customize the report as per your requirement.
Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
For further assistance, please connect with our analysts.
Gain a deeper dive into a specific application, geography, customer, or competitor
Any level of personalization
Get in Touch With Us
IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.
The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required
We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra
The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.
I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.
We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.